Evidence map›Paper›PMID 40715298›Full record

ArticleScientific reports2025

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer.

Laura Bauersachs, Marcus Beck, Christian Furth, Felix Mehrhof, Holger Amthauer, Pirus Ghadjar, Julian M M Rogasch, Maria de Santis, Rana Tahbaz, Daniel Zips and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura BauersachsDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Marcus BeckDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Christian FurthDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Felix MehrhofDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Holger AmthauerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Pirus GhadjarDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Julian M M RogaschDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Maria de SantisDepartment of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Rana TahbazDepartment of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Daniel ZipsDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Sebastian ZschaeckDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. Sebastian.Zschaeck@charite.de.ORCID http://orcid.org/0000-0003-3109-0662

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years there has been a growing interest in metastasis directed radiotherapy (MDRT) in hormone-sensitive oligometastatic prostate cancer. The role of MDRT in castration resistant prostate cancer (CRPC) patients remains controversial. Our study retrospectively compared MDRT to standard of care (SOC) in oligometastatic/oligoprogressive CRPC patients staged by PSMA PET CT. Patients either received SOC or MDRT with continuation of androgen deprivation therapy (ADT). Investigated endpoints contained biochemical progression-free survival (bPFS), overall survival (OS) and freedom from second line therapy (FFSLT). In this retrospective monocenter study, all patients with PSMA PET between January 2014 and July 2018 were screened. 55 oligometastatic/oligoprogressive CRPC patients were identified and further analysed, 34 received MDRT and 21 SOC. Baseline characteristics were similarly distributed between groups. Kaplan-Meier estimates suggested a trend for improved bPFS (p = 0.10) and improved OS (p = 0.01) by MDRT. Additionally, FFSLT was significantly prolonged in MDRT patients (p = 0.006). Multivariate cox regression analyses revealed MDRT as the only parameter that was significantly associated with bPFS (hazard ratio 0.36, p = 0.048) and OS (hazard ratio 0.14, p = 0.006). No high-grade radiation induced toxicities were observed. In our study MDRT was a well-tolerated treatment option with low toxicity in oligometastatic/oligoprogressive CRPC patients, resulting in improved OS and freedom from second-line therapy and a potential improvement of bPFS compared to SOC.

Indexed as

Glutamate Carboxypeptidase IIProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAndrogen AntagonistsAntigens, SurfaceHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyRetrospective StudiesStandard of CareAndrogen AntagonistsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIAblative radiotherapyCastration resistant prostate cancerMetastasis directed radiotherapyOligometastatic prostate cancerOligoprogressive prostate cancerPositron emission tomographyPSMA PETSecond line androgen deprivation therapyStereotactic irradiation

Identifiers

PMID40715298
PMCPMC12297292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.